You're contacting media contact of this press release

Title: Lumikei Med Appoints Global Advisory Board to Champion Gender Equity in Clinical Research

Singapore, Singapore, 16th May 2025 - Lumikei Med, a purpose-led healthcare innovation company focused on advancing gender equity in clinical research, has appointed its inaugural Global Advisory Board in partnership with the Veblen Director Programme.Historically, women were underrepresented, and often excluded, from clinical research. A 1977 FDA guideline barred most women of childbearing age from early-phase trials, citing hormonal and reproductive concerns. Although reversed in 1993, disparities remain: women are still underrepresented in areas like cardiovascular disease, psychiatric conditions, and cancer, with the gap widest in early-phase trials and among women of colour. Moreover, trial data is not always analysed by sex, limiting understanding of treatment safety and efficacy across genders.Founded to address these gaps, Lumikei Med works at the intersection of advocacy, education, and ethical innovation to build a more inclusive and effective healthcare system—one that reflects the needs of all women, across all backgrounds.Through this new board, Lumikei gains access to Veblen’s global network of senior leaders, governance experts, and changemakers. Each member brings experience in healthcare strategy, patient advocacy, and impact-driven leadership to support Lumikei’s mission.Founded by Rubina Goel, Lumikei Med was born from a bold vision: to ensure that women’s voices, experiences, and health needs are no longer side-lined in medical innovation. “Lumikei Med – meaning ‘Light beyond form,’ translating to ‘Healing beyond limits’ – is on a mission to transform the future of healthcare through gender equity. By addressing long-standing gaps in representation, we aim to ensure that every woman, regardless of background, has access to he...

This press release is issued by King Newswire